PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12195238-0	2002	Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.	Naltrexone	114-124	interleukin 2	Homo sapiens	140-153	
12195238-1	2002	OBJECTIVES: The preliminary applications of the psychoneuroimmunological knowledges to the treatment of human diseases have confirmed the possibility to amplify IL-2-dependent anticancer immunity by the pineal hormone melatonin (MLT) or by opioid antagonist, such as naltrexone (NTX), which act by activating TH1 lymphocytes or suppressing TH2 lymphocytes, respectively.	Naltrexone	267-277	interleukin 2	Homo sapiens	161-165	
12195238-1	2002	OBJECTIVES: The preliminary applications of the psychoneuroimmunological knowledges to the treatment of human diseases have confirmed the possibility to amplify IL-2-dependent anticancer immunity by the pineal hormone melatonin (MLT) or by opioid antagonist, such as naltrexone (NTX), which act by activating TH1 lymphocytes or suppressing TH2 lymphocytes, respectively.	Naltrexone	279-282	interleukin 2	Homo sapiens	161-165	
12195238-3	2002	This preliminary study was carried out to evaluate whether the association of NTX may further enhance the lymphocytosis induced by the neuroimmunotherapy with IL-2 plus MLT.	Naltrexone	78-81	interleukin 2	Homo sapiens	159-163	
12195238-9	2002	However, the concomitant administration of NTX induced a significantly higher increase in lymphocyte mean number with respect to that achieved with IL-2 plus MLT alone.	Naltrexone	43-46	interleukin 2	Homo sapiens	148-152	
12195238-11	2002	CONCLUSIONS: This preliminary study shows that the association of NTX further amplifies the lymphocytosis obtained by IL-2 plus MLT.	Naltrexone	66-69	interleukin 2	Homo sapiens	118-122	
31736966-9	2019	Importantly, TRPM3 channel activity was restored in IL-2 stimulated NK cells isolated from ME/CFS patients after incubation for 24 h with NTX.	Naltrexone	138-141	interleukin 2	Homo sapiens	52-56	
12080288-0	2002	A new neuroimmunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on interleukin-2 alone.	Naltrexone	116-126	interleukin 2	Homo sapiens	172-185